Cabaletta Bio

CABA

Market cap $230M

2.39 USD

+0.03

1.27%

At close Updated Dec 15, 4:00 PM EST

Pre-market

After hours

2.39

0.00

1 day

1.27%

5 days

-4.4%

1 month

3 months

25.13%

6 months

23.2%

Year to date

2.58%

1 year

-11.81%

5 years

-83.98%

10 years

-76.1%

About: Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.

Employees: 151

Healthcare Biotechnology